
LQDA Stock Forecast & Price Target
LQDA Analyst Ratings
Bulls say
Liquidia is well-positioned in the PH and PH-ILD space with a strong product offering and potential for growth, but the company faces competition and legal risks. Its strong financials and focus on innovation and research make it a promising investment opportunity with a positive outlook.
Bears say
Liquidia is a biopharmaceutical company that has developed a technology called PRINT, which enables precise production of particles for drugs. However, the company's main product, YUTREPIA, faces competition from similar drugs and ongoing legal challenges that could result in significant financial penalties. Additionally, there are concerns about the company's ability to reach patients and expand into new indications. Based on the company's financials, its current value is estimated at $19/share, but the risks and challenges it faces could lead to a decline in its stock value.
This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.
LQDA Analyst Forecast & Price Prediction
Start investing in LQDA
Order type
Buy in
Order amount
Est. shares
0 shares